Wolfgang Miesbach: How to Better Understand and Explain Gene Therapy of Haemophilia?
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on Linkedin:
“How to better understand and explain gene therapy of haemophilia? Our latest publication, ‘Gene-based therapies for hemophilia,’ is now available as full-open access article in Research and Practice in Thrombosis and Haemostasis! This illustrated review provides a comprehensive overview of gene therapy for hemophilia A and B, highlighting how recent advances are transforming patient care.
Through 10 detailed figures, the article breaks down complex concepts into clear visuals, making it easier for both patients and healthcare professionals (HCPs) to understand:
· Mechanisms of gene therapy: How adeno-associated virus (AAV) vectors deliver functional FVIII or FIX genes to address the root cause of hemophilia
· Clinical outcomes: Visual summaries of trial results for therapies like valoctocogene roxaparvovec, etranacogene dezaparvovec, and fidanacogene elaparvovec, showing sustained factor production and reduced bleeding episodes
· Benefits for patients: Figures illustrate the potential for long-term freedom from regular infusions and improved quality of life
· Challenges and future directions: Visuals explain ongoing issues such as immune responses, hepatotoxicity, and strategies for expanding eligibility and durability
These figures are invaluable for:
· Educating patients about what gene therapy means for their treatment journey
· Empowering HCPs with up-to-date, evidence-based visuals to support informed discussions and shared decision-making
Read the full open-access article to explore all 10 figures and deepen your understanding of gene therapy’s promise for haemophilia patients.”
-
Oct 14, 2025, 06:19Kay Sharma: I Feel Incredibly Proud and Honored to Share the Final Agenda for The ISTH Continuing Education Forum
-
Oct 14, 2025, 06:12Murray Adams: Professor Favaloro Presented Talks On The 100-Year History of von Willebrand Disease
-
Oct 14, 2025, 06:10Samuel Nweke on Significance of MPV in a CBC in Diagnosis
-
Oct 14, 2025, 06:09Francois Delvoye: 5 Days to Go Before the Belgian Stroke Council Scientific Workshop!
-
Oct 14, 2025, 06:08David Smadja: Honored to Take Part in This Special Event for World Thrombosis Day at UM6P University
-
Oct 14, 2025, 06:13Amaliris Guerra: Driving True Innovation in Preclinical Drug Development Related to Iron-Metabolism and Inflammation is One of My Passions!
-
Oct 13, 2025, 03:32Wolfgang Miesbach: This Study from Children's Hospital of Philadelphia Provides Crucial Insights Into Elevidys
-
Oct 13, 2025, 02:43Lukas Meyer and Colleagues on Reperfusion-dependent Treatment Effects of Thrombectomy in Large Ischemic Infarcts
-
Oct 12, 2025, 10:14Hatim Lokhandwala: Landmark HI-PRO Trial Redefines VTE Treatment Guidelines
-
Oct 12, 2025, 07:28Roberta Gualtierotti: rFVIIIFc and rFIXFc Ensured Effective Haemostasis and Favourable Safety in Major Orthopaedic Surgery
-
Oct 13, 2025, 02:46Flora Peyvandi: First Proposed Blood Test for Chronic Fatigue Syndrome - What Scientists Think
-
Oct 13, 2025, 02:44Silvio Maresca: Honored to be part of this international research project - ThrombUS+
-
Oct 10, 2025, 12:25Robert Lewis: T Cells Are Wonderful - But They Can't Do Everything
-
Oct 9, 2025, 13:03Peter Graves: When the Bleeding Does Not Stop
-
Oct 8, 2025, 12:44Bobur Kholikov: Thrombosis Diagnostics with YHLO
-
Oct 14, 2025, 06:11Souad Ahmed: It Was Such A Treat to Attend the 2025 AIMS Travelling Orator Session
-
Oct 14, 2025, 06:06Tara Miller: One of My Favorite Parts of My Job Is Partnering With Passionate Teams Like ISTH
-
Oct 14, 2025, 06:05Pierre Grès: Honored to Share With You My Recent Award for Best Oral Presentation And My Experiences at The Congress of SFTH
-
Oct 14, 2025, 01:16Louise Bannon: Thank You to My Dear Friend, Justin Romanello, Who Shared His Blood Clot Survivor Story With ISTH World Thrombosis Day Campaign
-
Oct 13, 2025, 03:44Jorge Monge: It Was An Honor to Take Part in the 3rd EBA Workshop on Rare Blood Provision